IRB Study Number 18-1080
Status Recruiting
Location Cleveland Clinic Main Campus
Institute Heart and Vascular Institute
Description
The purpose of this research study is to see if a study drug called Tocilizumab will, when given with standard anti-rejection medicines, lead to better heart transplant outcomes at 1 year after the transplant, Specifically, we will evaluate whether taking tocilizumab leads to less rejection, less development of unwanted antibodies, and better heart function.
Inclusion Criteria
- Candidate for primary heart transplant
- Patient is between the age of 18 and 75 at time of enrollment
Exclusion Criteria
- Candidate for a multiple solid organ or tissue transplants
- HVI positive patient
